Amphastar Pharma (AMPH) Reports Q3 Loss of $0.01/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Amphastar Pharmaceuticals Reports Net Revenues of $63.9 Million for the Third Quarter Ended September 30, 2015
November 12, 2015 4:06 PM ESTRANCHO CUCAMONGA, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company") today reported results for the third quarter ended September 30, 2015.
Net revenues of $63.9 million for the third quarter GAAP net loss of $3.0 million, or $0.07 per diluted share for the third quarter Adjusted non-GAAP net loss of $0.3 million, or $0.01 per diluted share for the third quarter  Three Months Ended September 30, Nine Months Ended September 30,  2015 2014 2015 2014  (in thousands, except per share data) Net revenues  $ 63,868... More